Summary of Use during Lactation

Minimal information on the clinical use of caplacizumab during breastfeeding found it to be well tolerated by the breastfed infant. Because caplacizumab is a large protein molecule with a molecular weight of about 28,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1] Until more data become available, caplacizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Some opinion recommends that patients with acquired thrombotic thrombocytopenic purpura not breastfeed because anti-platelet sIgA might be present in milk and may adversely affect the infant.[2]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]

2.

Alijotas-Reig J. Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain. Thromb Res. 2017;156:195–7. [PubMed: 28697902]

Substance Name

Caplacizumab

CAS Registry Number

915810-67-2

Drug Class

Breast feeding

Lactation

Milk, Human

Antibodies, Monoclonal

Single-Domain Antibodies